Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jun 23, 2025

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
08:34

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021

2.5K

康复性等离子体和美国扩展访问计划:一个个人叙述

Michael J Joyner1

  • 1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA. Joyner.Michael@mayo.edu.

Current topics in microbiology and immunology
|June 14, 2024
PubMed
概括

在近10万住院患者中,COVID-19康复性血 (CCP) 治疗证明了安全性和有效性. 早期使用高度CPC可显著降低三分之一的死亡率,支持其紧急使用授权.

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Non-invasive biomarkers for detecting progression toward hypovolemic cardiovascular instability in a lower body negative pressure model.

Scientific reports·2024
Same author

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.

mBio·2024
Same author

Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis.

Diseases (Basel, Switzerland)·2024
Same author

Convalescent plasma: An unexpected new therapeutic option for critically ill COVID-19 patients coming from the past.

Journal of clinical anesthesia·2024
Same author

Convalescent Plasma for Covid-19-Induced ARDS.

The New England journal of medicine·2024
Same author

Reflections on physiology and modelling.

Experimental physiology·2024

科学领域:

  • 免疫学 免疫学 免疫学
  • 传染性疾病 传染性疾病
  • 公共卫生 公共卫生

背景情况:

  • 由于COVID-19的流行,需要快速开发治疗策略.
  • COVID-19康复性血 (CCP) 已成为一种潜在的治疗选择.
  • 一个FDA授权的扩展访问计划 (EAP) 促进了广泛的CCP使用.

研究的目的:

  • 描述梅奥诊所托管的中枢诊所 EAP.的建立和结果.
  • 评估CCP在大量多样化的患者群体中的安全性和有效性.
  • 为未来的公共卫生危机分享所学到的经验.

主要方法:

  • 分析了近10万名EAP治疗的患者的临床数据.
  • 在5,000名和20,000名接受者的初始队列中进行安全评估.
  • 有效性评估侧重于通过早期,高位的CPT管理来降低死亡率.

主要成果:

  • 在2200家美国医院中实施了CPT治疗,为多样化的患者群体提供服务.
  • 早期的安全信号在计划启动后的几周内被发现.
  • 在住院早期使用高滴度的CPC可将死亡率降低高达33%.

结论:

  • 中央对手EAP证明了大规模的协作治疗努力的可行性和益处.
  • 早期给予的CCP,特别是高滴度血,在降低COVID-19死亡率方面被证明是有效的.
  • 该计划为管理未来的流行病和治疗性血使用提供了宝贵的见解.
关键词:
抗体是对抗体的一种.生物医学先进研究和开发机构康复期间的血.扩展访问程序扩展访问程序

更多相关视频

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

9.9K
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.1K

相关实验视频

Last Updated: Jun 23, 2025

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
08:34

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021

2.5K
Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

9.9K
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.1K